2020
Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19
Fu Y, Li Y, Guo E, He L, Liu J, Yang B, Li F, Wang Z, Li Y, Xiao R, Liu C, Huang Y, Wu X, Lu F, You L, Qin T, Wang C, Li K, Wu P, Ma D, Sun C, Chen G. Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19. Annals Of Internal Medicine 2020, 174: m20-3337. PMID: 33284684, PMCID: PMC7745119, DOI: 10.7326/m20-3337.Peer-Reviewed Original ResearchConceptsIndependent risk factorLaboratory-confirmed COVID-19Noncritically ill patientsViral positivityCritically ill patientsIll patientsDisease severityLow IgM titersRisk factorsViral polymerase chain reactionIgM titersCourse of coronavirus disease 2019Serum inflammatory markersIgM positive rateClinically diagnosed casesIgG positivity rateViral positivity rateMedian durationSpecialty care centersSeroconversion ratesAdult patientsInflammatory markersSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Polymerase chain reactionPrior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma
Gong Y, Fan Z, Luo G, Huang Q, Qian Y, Cheng H, Jin K, Ni Q, Yu X, Liu C. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Pancreatology 2020, 20: 716-721. PMID: 32249060, DOI: 10.1016/j.pan.2020.02.016.Peer-Reviewed Original ResearchConceptsHistory of APPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma patientsLog-rank testAcute pancreatitisSurgical resectionDuctal adenocarcinomaPoor survivalHazard ratioHistory of acute pancreatitisDiagnosis of pancreatic ductal adenocarcinomaAssociated with poor survivalIndependent survival predictorMultivariable-adjusted hazard ratiosKaplan-Meier methodRetrospective cohort studyCox proportional hazards modelsProportional hazards modelOverall survivalRemote historyClinical characteristicsCohort studyMultivariate analysisRisk factorsDevelopment and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia
Wu C, Luedtke A, Sadikova E, Tsai H, Liao S, Liu C, Gau S, VanderWeele T, Kessler R. Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. JAMA Network Open 2020, 3: e1921660. PMID: 32083693, PMCID: PMC7043195, DOI: 10.1001/jamanetworkopen.2019.21660.Peer-Reviewed Original ResearchConceptsFirst-episode schizophreniaAntipsychotic medicationPrescribed antipsychotic medicationTreatment success rateTreatment successSchizophrenic disordersFirst-episodeSuccess rateSchizophreniaProbability of treatment successTaiwan National Health Insurance Research DatabaseNational Health Insurance Research DatabaseHealth Insurance Research DatabaseEstimating treatment successValidation sampleIndividualized treatment rulesMedicationPrognostic studyPatientsInvestigated biomarkersClinical implementationDischarge diagnosisClinical observationsDemographic dataPragmatic trialKras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesTime FactorsT-Lymphocytes, RegulatoryConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stageClinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase
Chien Y, Hwu H, Hwang T, Hsieh M, Liu C, Lin-Shiau S, Liu C. Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2020, 99: 109868. PMID: 31954755, DOI: 10.1016/j.pnpbp.2020.109868.Peer-Reviewed Original ResearchConceptsChronic stable schizophreniaNon-psychiatric controlsDisorganized symptomsChronic stable patientsStable schizophreniaWeeks of antipsychotic treatmentStages of schizophreniaAcute relapseClinical implicationsAntipsychotic treatmentNegative symptomsSchizophreniaStable patientsOxidative stressPlatelet superoxide dismutasePlatelet oxidative stressTreatment responseNitric oxideLipid peroxidationLevels of nitric oxideSymptomsSuperoxide dismutaseTreatment effectsRelapsed patientsRelapseResected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
Liu C, Cheng H, Jin K, Fan Z, Gong Y, Qian Y, Deng S, Huang Q, Ni Q, Yu X, Luo G. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Cancer Control 2020, 27: 1073274820915947. PMID: 32268796, PMCID: PMC7153189, DOI: 10.1177/1073274820915947.Peer-Reviewed Original ResearchConceptsGemcitabine-based adjuvant chemotherapyResectable pancreatic cancerPancreatic cancerAdjuvant chemotherapyN2 node involvementNode involvementCurative resection of pancreatic adenocarcinomaResection of pancreatic adenocarcinomaGemcitabine-based regimenGemcitabine-based treatmentNode-positive subgroupEfficacy of gemcitabineGemcitabine-based chemotherapyN2 tumorsAdjuvant regimenNodal involvementNodal statusNode-negativeCurative resectionPancreatic adenocarcinomaSubgroup patientsLymphatic metastasisChemotherapyPatientsCancer
2019
AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
Fan Z, Cheng H, Jin K, Gong Y, Huang Q, Xu J, Ni Q, Yu X, Liu C, Luo G. AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. World Journal Of Surgical Oncology 2019, 17: 137. PMID: 31387646, PMCID: PMC6685146, DOI: 10.1186/s12957-019-1682-9.Peer-Reviewed Original ResearchConceptsInvasive IPMNInvasive intraductal papillary mucinous neoplasmStage IB diseaseStage IIA diseaseHazard ratioEdition classificationIIA diseaseIB diseaseStaging classificationStaging systemEnd Results cancer registryIntraductal papillary mucinous neoplasmEdition staging systemPredictors of survivalAmerican Joint CommitteeCancer (AJCC) staging systemPapillary mucinous neoplasmConclusionsThe AJCCResectable tumorsAJCC stagingStage IIACancer RegistryTumor sizeMucinous neoplasmsResultsIn total
2018
Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma
Liu C, Cheng H, Jin K, Guo M, Lu Y, Wang Z, Yang C, Long J, Ni Q, Yu X, Luo G. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Pancreas 2018, 47: 742-747. PMID: 29851752, DOI: 10.1097/mpa.0000000000001073.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerAmerican Joint Committee on Cancer stageTumor resectionPancreatic cancerEighth editionAmerican Joint Committee on Cancer eighth editionAmerican Joint Committee on Cancer seventh editionStage classificationLymph node involvementEnd Results registrySeventh editionPrognosis to patientsNode involvementTumor diameterPositive nodesInstitutional seriesPancreatic adenocarcinomaCancer stageStage distributionSurvival curvesPatientsSurvival analysisTumorStatistical differenceCancer
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune responseSeroprevalence survey of selective anti-neuronal autoantibodies in patients with first-episode schizophrenia and chronic schizophrenia
Chen C, Cheng M, Liu C, Liu C, Lin K, Hwu H. Seroprevalence survey of selective anti-neuronal autoantibodies in patients with first-episode schizophrenia and chronic schizophrenia. Schizophrenia Research 2017, 190: 28-31. PMID: 28341002, DOI: 10.1016/j.schres.2017.03.012.Peer-Reviewed Original ResearchConceptsAnti-neuronal autoantibodiesLeucine-rich glioma-inactivated-1N-methyl-D-aspartateContactin-associated protein-like 2First-episode schizophreniaAnti-NMDA receptor autoantibodiesA-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acidAssociated with psychiatric disordersGlioma-inactivated-1Blood samplesNeuronal cell surface proteinsArchived blood samplesNeuronal surface proteinsCerebral spinal fluidProtein-like 2Chronic schizophreniaReceptor autoantibodiesClinical presentationAutoimmune encephalopathyTreatment resistancePsychiatric disordersCorrect diagnosisSchizophreniaAutoantibodiesSpinal fluid
2016
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016, 16: 1057-1062. PMID: 27692554, DOI: 10.1016/j.pan.2016.09.013.Peer-Reviewed Original ResearchConceptsDetect pancreatic cancerCut-off valueSensitivity of CA19-9CA19-9Pancreatic cancerEffectiveness of CA19-9Secretor genotypeStaging of pancreatic cancerII pancreatic cancerDetection of stage INegative predictive valueCohort of subjectsCA19Carbohydrate antigenStage IPredictive valueSanger sequencingCancerSecretor statusSecretorEarly detectorGenotypic backgroundGroupThe Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal Of Molecular Sciences 2016, 17: 1090. PMID: 27399694, PMCID: PMC4964466, DOI: 10.3390/ijms17071090.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesConceptsAdjuvant chemotherapyPostoperative survivalEGFR statusOverall survivalSurvival benefitEGFR expressionPancreatic cancerProlonged median overall survivalResected pancreatic cancer patientsAssociated with improved survivalSurgically resected pancreatic cancerMedian overall survivalResectable pancreatic cancerSignificant survival benefitEpidermal growth factor receptorKaplan-Meier analysisPancreatic cancer patientsPancreatic cancer treatmentStudies of EGFRGrowth factor receptorResectable PDACAdjuvant therapyPrognostic significanceImproved survivalExpression subgroupsWhich patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?
Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget 2016, 7: 29177-29186. PMID: 27081079, PMCID: PMC5045387, DOI: 10.18632/oncotarget.8690.Peer-Reviewed Original ResearchConceptsPancreatic head cancerResectable pancreatic head cancerLymph node ratioHead cancerLymph nodesTumor locationPara-aortic lymph node dissectionPara-aortic lymph node metastasisPara-aortic lymph nodesCurative surgical resectionLymph node dissectionIndependent prognostic factorLymph node metastasisPoor surgical outcomesDuctal adenocarcinoma patientsPoor prognostic markerPreoperative serum CA125Curative pancreaticoduodenectomyNode dissectionPancreatic headRadical surgerySurgical resectionNode metastasisPrognostic factorsSuch patientsImpact of universal health coverage on urban–rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan
Chiang C, Chen P, Huang L, Kuo P, Tung Y, Liu C, Chen W. Impact of universal health coverage on urban–rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan. BMJ Open 2016, 6: e010802. PMID: 26940114, PMCID: PMC4785302, DOI: 10.1136/bmjopen-2015-010802.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmbulatory CareDatabases, FactualFemaleHealthcare DisparitiesHumansKaplan-Meier EstimateLogistic ModelsMaleMental Health ServicesMiddle AgedNational Health ProgramsPatient AdmissionPsychotic DisordersRetrospective StudiesRural PopulationTaiwanUniversal Health InsuranceUrban PopulationYoung AdultConceptsUniversal health coverageService utilisationUrban-rural residenceUrban-rural inequalitiesHealth coverageUrban patientsEmergency departmentImplementation of universal health coverageImpacts of universal health coverageNationwide population-based studyQuality of careTaiwan National Health Insurance Research DatabaseNational Health Insurance Research DatabaseRural-dwelling patientsHealth Insurance Research DatabasePopulation-based studyUrban-rural differencesPopulation coverage ratePsychiatric outpatient servicesMedical claims recordsNationwide cohort of patientsRisk of readmissionRural patientsUrban-rural gapPsychiatric readmissionAberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue
Lai C, Lee S, Scarr E, Yu Y, Lin Y, Liu C, Hwang T, Hsieh M, Liu C, Chien Y, Udawela M, Gibbons A, Everall I, Hwu H, Dean B, Chen W. Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. Translational Psychiatry 2016, 6: e717-e717. PMID: 26784971, PMCID: PMC5068884, DOI: 10.1038/tp.2015.213.Peer-Reviewed Original ResearchConceptsPeripheral miRNAsState-dependent markersDiagnostic of schizophreniaHsa-miR-34aPostmortem brain tissueAberrant expression of microRNAsCaudate putamenSchizophreniaSubcortical regionsAcute stateExpression of microRNAsSeven-miRNARemission stateBrain samplesAberrant expressionClinically useful biomarkersExpression levelsBrainMonths of hospitalizationPartial remission stateAge-dependent increaseMiRNA dysregulationMiRNAsPartial remissionClinical symptoms
2015
Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial
Xu J, Zhang B, Shi S, Qin Y, Ji S, Xu W, Liu J, Liu L, Liu C, Long J, Ni Q, Yu X. Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. Surgery 2015, 158: 1211-1218. PMID: 26036878, DOI: 10.1016/j.surg.2015.04.020.Peer-Reviewed Original ResearchConceptsNondilated main pancreatic ductPostoperative pancreatic fistulaPostoperative pancreatic fistula rateDuct-to-mucosa pancreaticojejunostomyDuct-to-mucosa groupMain pancreatic ductPancreatic ductIncidence of grade B/C postoperative pancreatic fistulasGrade B/C postoperative pancreatic fistulaB/C postoperative pancreatic fistulaDilated main pancreatic ductHigher body mass indexSignificant risk factorsBody mass indexLonger operative timePOPF rateInvagination pancreaticojejunostomyPancreatic fistulaPancreatic anastomosisRetrospective studyPancreaticojejunostomyMass indexMultivariate analysisOperative timePancreaticoduodenectomyLymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinomaMetabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, Ni Q, Yu X. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters 2015, 360: 227-233. PMID: 25687883, DOI: 10.1016/j.canlet.2015.02.014.Peer-Reviewed Original ResearchConceptsMetabolic tumor burdenMetabolic tumor volumeSerum tumor markersTumor burdenTumor markersPancreatic cancerAbnormal expressions of TP53Abnormal expressionMonitoring treatment responsePancreatic cancer patientsProgression of pancreatic cancerExpression of TP53Tumor volumeCA19-9SMAD4/DPC4 geneTreatment responseCancer patientsDisease progressionPET/CTPredictive significanceSurvival rateLethal diseasePatientsCancerSerum
2014
Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals Of Surgical Oncology 2014, 22: 670-676. PMID: 25155401, DOI: 10.1245/s10434-014-4021-y.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioBaseline neutrophil-to-lymphocyte ratioAdvanced pancreatic cancerNLR changeOverall survivalPancreatic cancerPrognostic roleMultivariate analysisPredictor of overall survivalSerum CA19-9 levelsPredictor of poor survivalAdvanced pancreatic adenocarcinomaCA19-9 levelsSerum albumin levelCox proportional hazards modelsProportional hazards modelPostchemotherapy changesClinicopathological predictorsDistant metastasisPrognostic factorsPancreatic adenocarcinomaClinicopathological characteristicsAlbumin levelsPoor survivalPredicting survival18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Xu J, Zhang B, Liu C, Huang D, Hu S, Ni Q, Long J, Yu X. 18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. International Journal Of Oncology 2014, 45: 1531-1536. PMID: 25096059, DOI: 10.3892/ijo.2014.2570.Peer-Reviewed Original ResearchConceptsNon-functioning pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsPET/CTNeuroendocrine tumorsNon-functioning endocrine pancreatic tumorsPET/CT scansDistant metastatic lesionsShanghai Cancer CenterEndocrine pancreatic tumorsClinical characteristicsMetastatic lesionsTumor sizeCancer CenterTNM stagePancreatic tumorsLarge cohortCT scanClinical valueAdvanced stageSignificant associationTumorsPatientsCTCohortLesions